Ayad Michael, Eskioglu Eric, Mericle Robert A
Vanderbilt University, Department of Neurological Surgery, Vanderbilt University Medical Center, MCN T-4224, Nashville, TN 37212, USA.
Expert Rev Med Devices. 2006 Nov;3(6):705-15. doi: 10.1586/17434440.3.6.705.
Rupture of a cerebral arteriovenous malformation can result in devastating hemorrhage with a possibility of serious neurological injury or death. Endovascular embolization is an important adjunct in the treatment of cerebral arteriovenous malformations, and in a small number of cases may provide definitive treatment. Currently available embolic agents have several shortcomings, including the possibility of recanalization, adhesiveness to the endovascular microcatheter and suboptimal handling at the time of surgical resection. Onyx is an ethylene vinyl alcohol copolymer dissolved in dimethyl sulfoxide that was approved by the US FDA in July 2005 as an embolic agent for brain arteriovenous malformations. Although long-term follow-up is limited, this agent appears to offer several advantages over the other available embolic agents for the endovascular management of arteriovenous malformations and other vascular lesions.
脑动静脉畸形破裂可导致毁灭性出血，有可能造成严重神经损伤或死亡。血管内栓塞是治疗脑动静脉畸形的重要辅助手段，在少数情况下可提供确定性治疗。目前可用的栓塞剂有几个缺点，包括再通的可能性、与血管内微导管的粘附性以及手术切除时的操作不理想。Onyx是一种溶解于二甲基亚砜的乙烯-乙烯醇共聚物，于2005年7月被美国食品药品监督管理局批准作为脑动静脉畸形的栓塞剂。尽管长期随访有限，但这种栓塞剂在动静脉畸形和其他血管病变的血管内治疗方面似乎比其他可用栓塞剂具有几个优势。
